Our lab recently contributed to a pivotal discovery in gene regulation, published in Nature (Coban et al., 2024; doi:10.1038/s41586-024-07576-w). This work revealed that antisense RNAs (asRNAs) can precisely modulate mRNA nuclear export, enabling targeted enhancement or inhibition of protein production in eukaryotic cells. For a detailed technical overview, learn more on ScienceBridge or contact us.
Key Insights
By designing asRNAs to bind complementary mRNA sequences in the nucleus, we demonstrated that double-stranded RNA (dsRNA) formation accelerates mRNA export via the Mex67-Mtr2 receptor, boosting translation efficiency. In proof-of-concept studies using Saccharomyces cerevisiae and human cells, this approach increased protein output over sevenfold within one hour. Conversely, tailored asRNA designs can block mRNA export, offering dual functionality for gene regulation.
Potential Applications
- Enhanced Recombinant Protein Yields: Improve production of therapeutic or industrial proteins in yeast or human cell systems.
- Therapeutic Correction: Restore deficient protein levels in genetic disorders or suppress pathological proteins in disease contexts.
- Research Flexibility: Customizable for any gene of interest, supporting drug development and functional genomics.
Collaboration Opportunities
This technology, protected under PCT/EP2024/066684, has been validated in yeast and human models. We are actively seeking academic and industry partners to explore licensing or collaborative applications. For further technical details, visit ScienceBridge.de.
Reference
Coban, I., Lamping, J. P., Hirsch, A. G., Wasilewski, S., Shomroni, O., Giesbrecht, O., Salinas, G., & Krebber, H. (2024). dsRNA formation leads to preferential nuclear export and gene expression. Nature, 631(8020), 432–438. https://doi.org/10.1038/s41586-024-07576-w